AUPH Aurinia Pharmaceuticals Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development and commercialization of LUPKYNIS, an immunosuppressant drug, plus pipeline advancement of aritinercept
• • Emphasis on aritinercept clinical development with noted risks of delays, effectiveness, and regulatory approval uncertainty
• • Strategic focus this year on patent litigation defense against generic competition, involving paragraph IV ANDA notices and infringement lawsuits
• • Notable quantitative metric: U.S. patents for LUPKYNIS extended through December 2037; ongoing significant patent litigation costs expected
• • Most noteworthy fact: Increased risk exposure due to patent law changes under Leahy-Smith America Invents Act affecting patent protection and litigation dynamics

Risk Factors

• • Regulatory risk: Failure to comply with Medicaid Drug Rebate Program reporting may trigger CMS penalties, FCA allegations, and potential termination risking U.S. reimbursement for LUPKYNIS
• • Geopolitical risk: Reliance on Otsuka for commercialization and supply in the Otsuka Territories; failure by either party may limit LUPKYNIS sales in these ex-U.S. markets
• • Operational risk: Dependence on Lonza contract manufacturing for LUPKYNIS supply, with shared facility capacity posing production and delivery vulnerabilities
• • Competitive risk: LUPKYNIS faces competition from BENLYSTA, GAZYVA, and off-label regimens including tacrolimus, limiting growth potential amid entrenched treatment practices
• • Financial risk: High commercial expenditures to maintain sales/marketing capabilities for LUPKYNIS sales growth increase cost structure and business risk

Management Discussion & Analysis

• • Revenue $283.1M, up 20% YoY; Net product sales $271.3M up 25%, License revenue $11.7M down 38%
• • Gross margin stable at 88%; Operating expenses $178.1M down 26% from $239.8M; Operating income $104.9M vs loss $4.7M
• • Best segment: Net product sales $271.3M up $55.2M; worst: License, collaboration $11.7M down $7.2M
• • Cash $398.0M, up $39.5M; Operating cash flow $135.7M vs $44.4M; Share repurchases $98.2M, no dividend disclosed
• • 2026 SG&A expected flat at ~$101.8M; R&D to increase; Risks from market penetration and raising capital if needed

What are the latest AUPH SEC filings in 2026?

Aurinia Pharmaceuticals Inc. (AUPH) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on June 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did AUPH file its most recent 10-K annual report?

Aurinia Pharmaceuticals Inc. (AUPH) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view AUPH 10-Q quarterly reports?

Aurinia Pharmaceuticals Inc. (AUPH)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every AUPH 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has AUPH filed recently?

Aurinia Pharmaceuticals Inc. (AUPH)'s most recent 8-K was filed on June 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find AUPH insider trading activity (Form 4)?

SignalX aggregates every AUPH Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does AUPH file with the SEC?

Aurinia Pharmaceuticals Inc. (AUPH) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AUPH filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Aurinia Pharmaceuticals Inc. (AUPH).

What is AUPH's SEC CIK number?

Aurinia Pharmaceuticals Inc. (AUPH)'s SEC CIK (Central Index Key) number is 1600620. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1600620 to look up all AUPH filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find AUPH return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Aurinia Pharmaceuticals Inc. (AUPH) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.